Related Experiment Video
Updated: Jun 29, 2025
Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion
Published on: August 29, 2018
Glioblastoma stem cell metabolism and immunity
Joseph Hawly1, Micaela G Murcar2, Alejandro Schcolnik-Cabrera3
1Faculty of Medicine and Medical Sciences, University of Balamand, Dekouaneh, Lebanon.
Abstract:
Despite enormous efforts being invested in the development of novel therapies for brain malignancies, there remains a dire need for effective treatments, particularly for pediatric glioblastomas. Their poor prognosis has been attributed to the fact that conventional therapies target tumoral cells, but not glioblastoma stem cells (GSCs). GSCs are characterized by self-renewal, tumorigenicity, poor differentiation, and resistance to therapy. These characteristics represent the fundamental tools needed to recapitulate the tumor and result in a relapse. The mechanisms by which GSCs alter metabolic cues and escape elimination by immune cells are discussed in this article, along with potential strategies to harness effector immune cells against GSCs. As cellular immunotherapy is making significant advances in a variety of cancers, leveraging this underexplored reservoir may result in significant improvements in the treatment options for brain malignancies.
Insights
Pediatric glioblastomas are hard to treat because therapies miss cancer stem cells. Harnessing immune cells offers a promising new strategy for brain cancer treatment.
Area of Science:
- Neuro-oncology
- Cancer Stem Cell Biology
- Immunotherapy
Background:
- Pediatric glioblastomas (GBMs) have a poor prognosis despite extensive research.
- Conventional therapies fail to target glioblastoma stem cells (GSCs), which drive tumor recurrence.
- GSCs possess self-renewal, tumorigenicity, and therapeutic resistance, contributing to treatment failure.
Purpose of the Study:
- To explore the mechanisms by which GSCs evade immune surveillance.
- To discuss strategies for utilizing effector immune cells against GSCs.
- To highlight the potential of cellular immunotherapy for brain malignancies.
Main Methods:
- Review of current literature on GSC biology and immune evasion.
- Analysis of metabolic alterations in GSCs.
- Exploration of cellular immunotherapy approaches.
Main Results:
- GSCs employ specific metabolic adaptations to escape immune elimination.
- GSCs' inherent characteristics promote tumor relapse.
- Cellular immunotherapy presents a viable, yet underexplored, therapeutic avenue.
Conclusions:
- Targeting GSCs is crucial for effective pediatric glioblastoma treatment.
- Harnessing the immune system, particularly through cellular immunotherapy, holds significant promise.
- Further research into immune-based strategies could revolutionize brain cancer therapy.
